RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Raw

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net income-104-2227504243486368961,1992,4442,1163,5138,0754,3383,9544,413
Depreciation and amortization20-37415375105145148210236286341421483
Stock-based compensation expense-5694198307459560507427464432602725885983
(Gains) losses on marketable and other securities, net-------------37-266118
Other non-cash items, net--10-34-24-30-34-45-64-1229135-569-3680-23
Deferred income taxes----67122360-319140131-76147746838757
Acquired In-Process Research And Development, Asset Acquisition--------------13
(Increase) decrease in accounts receivable2821590199624911443632694731,3561,927-708339554
Increase in inventories---4861112150314388336529494697272620
Increase in prepaid expenses and other assets-3653533879-2411356130-115241149120408
Increase in deferred revenue---------194294148-1203238228
Increase (Decrease) in Accounts Payable and Accrued Liabilities85011137162304254-23210445119866-138599735
Total adjustments20180-825159395695578109-249314-895-9946776408
Net cash provided by operating activities96-142-755847431,3311,4731,3072,1952,4302,6187,0815,0154,5944,421
Purchases of marketable and other securities6052404705775645578091,2771,8463,2023,2417,0487,48811,64616,617
Sales or maturities of marketable and other securities2774264393784763272745457761,6043,7852,2155,5519,44215,027
Capital expenditures1005749156333678512273383430615552590719756
Proceeds from sale of property, plant, and equipment--------------20
Payments for Libtayo intangible asset------------1,027208126
Acquisitions, net of cash acquired-------------5517
Net cash used in investing activities-434128-81-355-421-908-1,047-1,005-1,463-2,028-71-5,385-3,785-3,185-2,468
Proceeds from issuance of Common Stock1971964571262061272401152122,5751,6721,5201,1461,465
Payments in connection with Common Stock tendered for employee tax obligations--1631952681611433021871886811,0334467011,029
Repurchases of Common Stock--------42765,8471,6452,0832,2352,603
Other---------------33
Net cash used in financing activities243384-9877-209-263-700-24-77-252-1,970-1,006-1,009-1,790-2,200
Effect of exchange rate changes on cash, cash equivalents, and restricted cash--------------0-1
Net (decrease) increase in cash, cash equivalents, and restricted cash---------150577691221-382-249
Cash paid for interest (net of amounts capitalized)-152224211151922252356547353
Income Taxes Paid, Net----602764817552063421881,2181,502870743